Landry Robert E sold 1,000 CYTOKINETICS INC shares at $74.66 each on Sep 11, 2026. The transaction reduced his prior holding by about 9.8%, leaving him with 9,184 shares. For investors, the disclosure identifies both the size of the director’s sale and his remaining position.
Key Highlights
- Landry Robert E held 9,184 CYTOKINETICS INC shares after the transaction.
- The transaction used code S, denoting an open-market sale.
- Landry Robert E is a director of CYTOKINETICS INC.
Landry Robert E sold 1,000 shares of CYTOKINETICS INC at $74.66 per share on Sep 11, 2026. The transaction reduced his position in the company. The disclosed sale was classified under transaction code S.
Director Sale and Transaction Code
The reported price was $74.66 per share. The transaction involved 1,000 shares. The sale date was Sep 11, 2026.
Remaining Holding After the Sale
Landry Robert E owned 9,184 CYTOKINETICS INC shares after completing the transaction. The sale represented about 9.8% of his prior shares holding. That percentage places the disclosed transaction against the size of his position before the sale, while the remaining balance identifies his ownership afterward. Transaction code S denotes an open-market or private sale.
FAQs
Q: How many CYTOKINETICS INC shares did Landry Robert E sell?
A: Landry Robert E sold 1,000 CYTOKINETICS INC shares at $74.66 per share. The transaction took place on Sep 11, 2026.
Q: What was the impact of Landry Robert E’s share sale?
A: The transaction reduced Landry Robert E’s prior share holding by about 9.8%. He owned 9,184 CYTOKINETICS INC shares after the sale.
Q: What does transaction code S mean in this insider transaction?
A: Transaction code S identifies the disclosed transaction as a sale. In this case, Landry Robert E sold 1,000 CYTOKINETICS INC shares at $74.66 per share on Sep 11, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.